Research programme: CAR based cell therapies - Janssen Biotech
Latest Information Update: 23 Jun 2022
At a glance
- Originator Janssen Biotech
- Developer Janssen Biotech; Serotiny
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Unspecified